生物製剤・バイオシミラーの世界及び中国市場

• 英文タイトル：Global and China Biologics and Biosimilars Market Insights, Forecast to 2027

• レポートコード：QY2108PAL8778 • 出版社/出版日：QYResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、158ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の当調査資料ではグローバルにおける生物製剤・バイオシミラーの市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、生物製剤・バイオシミラーの種類別市場規模（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他）、用途別市場規模（腫瘍、糖尿病、心血管、血友病、その他）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界の生物製剤・バイオシミラー市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界における生物製剤・バイオシミラーの種類別市場規模（2016年-2027年）：モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他 ・世界における生物製剤・バイオシミラーの用途別市場規模（2016年-2027年）：腫瘍、糖尿病、心血管、血友病、その他 ・生物製剤・バイオシミラーの中国市場分析 - 生物製剤・バイオシミラーの中国市場規模（2016年-2027年） - 中国における生物製剤・バイオシミラーの主要プレイヤー別市場シェア - 中国における生物製剤・バイオシミラーの種類別市場規模：モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他 - 中国における生物製剤・バイオシミラーの用途別市場規模：腫瘍、糖尿病、心血管、血友病、その他 ・生物製剤・バイオシミラーの北米市場（2016年-2027年） ・生物製剤・バイオシミラーのヨーロッパ市場（2016年-2027年） ・生物製剤・バイオシミラーのアジア太平洋市場（2016年-2027年） ・生物製剤・バイオシミラーの中南米市場（2016年-2027年） ・生物製剤・バイオシミラーの中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：Roche、Amgen、AbbVie、Sanofi-Aventis、Johnson & Johnson、Pfizer、Novo Nordisk、Eli Lilly、Novartis、Merck、3sbio、Changchun High Tech、CP Guojian、Biotech、Gelgen、Innovent、Dong Bao、Ganlee、United Laboratories ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・...

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product’s patent expires.
The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Market Analysis and Insights: Global and China Biologics and Biosimilars Market
This report focuses on global and China Biologics and Biosimilars market.
In 2020, the global Biologics and Biosimilars market size was US$ 182380 million and it is expected to reach US$ 260090 million by the end of 2027, with a CAGR of 5.1% during 2021-2027. In China the Biologics and Biosimilars market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Biologics and Biosimilars Scope and Market Size
Biologics and Biosimilars market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Biologics and Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Biologics and Biosimilars market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories

レポート目次

---

1 Study Coverage
1.1 Biologics and Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Biologics and Biosimilars Market Size Growth Rate by Type
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Market by Application
1.3.1 Global Biologics and Biosimilars Market Size Growth Rate by Application
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Biologics and Biosimilars Market Size, Estimates and Forecasts
2.1.1 Global Biologics and Biosimilars Revenue 2016-2027
2.1.2 Global Biologics and Biosimilars Sales 2016-2027
2.2 Global Biologics and Biosimilars, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Biologics and Biosimilars Historical Market Size by Region (2016-2021)
2.3.1 Global Biologics and Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Biologics and Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Biologics and Biosimilars Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Biologics and Biosimilars Sales Forecast by Region (2022-2027)
2.4.2 Global Biologics and Biosimilars Revenue Forecast by Region (2022-2027)

3 Global Biologics and Biosimilars Competitor Landscape by Players
3.1 Global Top Biologics and Biosimilars Manufacturers by Sales
3.1.1 Global Biologics and Biosimilars Sales by Manufacturer (2016-2021)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Biologics and Biosimilars Manufacturers by Revenue
3.2.1 Key Biologics and Biosimilars Manufacturers Covered: Ranking by Revenue
3.2.2 Global Biologics and Biosimilars Revenue by Manufacturers (2016-2021)
3.2.3 Global Biologics and Biosimilars Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Biologics and Biosimilars Revenue in 2020
3.2.6 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Biologics and Biosimilars Price by Manufacturers
3.4 Global Biologics and Biosimilars Manufacturing Base Distribution, Product Types
3.4.1 Biologics and Biosimilars Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biologics and Biosimilars Product Type
3.4.3 Date of International Manufacturers Enter into Biologics and Biosimilars Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)
4.1 Global Biologics and Biosimilars Market Size by Type (2016-2021)
4.1.1 Global Biologics and Biosimilars Sales by Type (2016-2021)
4.1.2 Global Biologics and Biosimilars Revenue by Type (2016-2021)
4.1.3 Biologics and Biosimilars Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Biologics and Biosimilars Market Size Forecast by Type (2022-2027)
4.2.1 Global Biologics and Biosimilars Sales Forecast by Type (2022-2027)
4.2.2 Global Biologics and Biosimilars Revenue Forecast by Type (2022-2027)
4.2.3 Biologics and Biosimilars Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)
5.1 Global Biologics and Biosimilars Market Size by Application (2016-2021)
5.1.1 Global Biologics and Biosimilars Sales by Application (2016-2021)
5.1.2 Global Biologics and Biosimilars Revenue by Application (2016-2021)
5.1.3 Biologics and Biosimilars Price by Application (2016-2021)
5.2 Biologics and Biosimilars Market Size Forecast by Application (2022-2027)
5.2.1 Global Biologics and Biosimilars Sales Forecast by Application (2022-2027)
5.2.2 Global Biologics and Biosimilars Revenue Forecast by Application (2022-2027)
5.2.3 Global Biologics and Biosimilars Price Forecast by Application (2022-2027)

6 China by Players, Type and Application
6.1 China Biologics and Biosimilars Market Size YoY Growth 2016-2027
6.1.1 China Biologics and Biosimilars Sales YoY Growth 2016-2027
6.1.2 China Biologics and Biosimilars Revenue YoY Growth 2016-2027
6.1.3 China Biologics and Biosimilars Market Share in Global Market 2016-2027
6.2 China Biologics and Biosimilars Market Size by Players (International and Local Players)
6.2.1 China Top Biologics and Biosimilars Players by Sales (2016-2021)
6.2.2 China Top Biologics and Biosimilars Players by Revenue (2016-2021)
6.3 China Biologics and Biosimilars Historic Market Review by Type (2016-2021)
6.3.1 China Biologics and Biosimilars Sales Market Share by Type (2016-2021)
6.3.2 China Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
6.3.3 China Biologics and Biosimilars Price by Type (2016-2021)
6.4 China Biologics and Biosimilars Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Biologics and Biosimilars Sales Forecast by Type (2022-2027)
6.4.2 China Biologics and Biosimilars Revenue Forecast by Type (2022-2027)
6.4.3 China Biologics and Biosimilars Price Forecast by Type (2022-2027)
6.5 China Biologics and Biosimilars Historic Market Review by Application (2016-2021)
6.5.1 China Biologics and Biosimilars Sales Market Share by Application (2016-2021)
6.5.2 China Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
6.5.3 China Biologics and Biosimilars Price by Application (2016-2021)
6.6 China Biologics and Biosimilars Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Biologics and Biosimilars Sales Forecast by Application (2022-2027)
6.6.2 China Biologics and Biosimilars Revenue Forecast by Application (2022-2027)
6.6.3 China Biologics and Biosimilars Price Forecast by Application (2022-2027)

7 North America
7.1 North America Biologics and Biosimilars Market Size YoY Growth 2016-2027
7.2 North America Biologics and Biosimilars Market Facts & Figures by Country
7.2.1 North America Biologics and Biosimilars Sales by Country (2016-2021)
7.2.2 North America Biologics and Biosimilars Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada

8 Asia Pacific
8.1 Asia Pacific Biologics and Biosimilars Market Size YoY Growth 2016-2027
8.2 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Region
8.2.1 Asia Pacific Biologics and Biosimilars Sales by Region (2016-2021)
8.2.2 Asia Pacific Biologics and Biosimilars Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam

9 Europe
9.1 Europe Biologics and Biosimilars Market Size YoY Growth 2016-2027
9.2 Europe Biologics and Biosimilars Market Facts & Figures by Country
9.2.1 Europe Biologics and Biosimilars Sales by Country (2016-2021)
9.2.2 Europe Biologics and Biosimilars Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy

10 Latin America
10.1 Latin America Biologics and Biosimilars Market Size YoY Growth 2016-2027
10.2 Latin America Biologics and Biosimilars Market Facts & Figures by Country
10.2.1 Latin America Biologics and Biosimilars Sales by Country (2016-2021)
10.2.2 Latin America Biologics and Biosimilars Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Biologics and Biosimilars Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
11.2.1 Middle East and Africa Biologics and Biosimilars Sales by Country (2016-2021)
11.2.2 Middle East and Africa Biologics and Biosimilars Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 Roche
12.1.1 Roche Corporation Information
12.1.2 Roche Description and Business Overview
12.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Roche Biologics and Biosimilars Products Offered
12.1.5 Roche Recent Development
12.2 Amgen
12.2.1 Amgen Corporation Information
12.2.2 Amgen Description and Business Overview
12.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Amgen Biologics and Biosimilars Products Offered
12.2.5 Amgen Recent Development
12.3 AbbVie
12.3.1 AbbVie Corporation Information
12.3.2 AbbVie Description and Business Overview
12.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.3.4 AbbVie Biologics and Biosimilars Products Offered
12.3.5 AbbVie Recent Development
12.4 Sanofi-Aventis
12.4.1 Sanofi-Aventis Corporation Information
12.4.2 Sanofi-Aventis Description and Business Overview
12.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sanofi-Aventis Biologics and Biosimilars Products Offered
12.4.5 Sanofi-Aventis Recent Development
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Corporation Information
12.5.2 Johnson & Johnson Description and Business Overview
12.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Johnson & Johnson Biologics and Biosimilars Products Offered
12.5.5 Johnson & Johnson Recent Development
12.6 Pfizer
12.6.1 Pfizer Corporation Information
12.6.2 Pfizer Description and Business Overview
12.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Pfizer Biologics and Biosimilars Products Offered
12.6.5 Pfizer Recent Development
12.7 Novo Nordisk
12.7.1 Novo Nordisk Corporation Information
12.7.2 Novo Nordisk Description and Business Overview
12.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Novo Nordisk Biologics and Biosimilars Products Offered
12.7.5 Novo Nordisk Recent Development
12.8 Eli Lilly
12.8.1 Eli Lilly Corporation Information
12.8.2 Eli Lilly Description and Business Overview
12.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Eli Lilly Biologics and Biosimilars Products Offered
12.8.5 Eli Lilly Recent Development
12.9 Novartis
12.9.1 Novartis Corporation Information
12.9.2 Novartis Description and Business Overview
12.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Novartis Biologics and Biosimilars Products Offered
12.9.5 Novartis Recent Development
12.10 Merck
12.10.1 Merck Corporation Information
12.10.2 Merck Description and Business Overview
12.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Merck Biologics and Biosimilars Products Offered
12.10.5 Merck Recent Development
12.11 Roche
12.11.1 Roche Corporation Information
12.11.2 Roche Description and Business Overview
12.11.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Roche Biologics and Biosimilars Products Offered
12.11.5 Roche Recent Development
12.12 Changchun High Tech
12.12.1 Changchun High Tech Corporation Information
12.12.2 Changchun High Tech Description and Business Overview
12.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Changchun High Tech Products Offered
12.12.5 Changchun High Tech Recent Development
12.13 CP Guojian
12.13.1 CP Guojian Corporation Information
12.13.2 CP Guojian Description and Business Overview
12.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.13.4 CP Guojian Products Offered
12.13.5 CP Guojian Recent Development
12.14 Biotech
12.14.1 Biotech Corporation Information
12.14.2 Biotech Description and Business Overview
12.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Biotech Products Offered
12.14.5 Biotech Recent Development
12.15 Gelgen
12.15.1 Gelgen Corporation Information
12.15.2 Gelgen Description and Business Overview
12.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Gelgen Products Offered
12.15.5 Gelgen Recent Development
12.16 Innovent
12.16.1 Innovent Corporation Information
12.16.2 Innovent Description and Business Overview
12.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Innovent Products Offered
12.16.5 Innovent Recent Development
12.17 Dong Bao
12.17.1 Dong Bao Corporation Information
12.17.2 Dong Bao Description and Business Overview
12.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Dong Bao Products Offered
12.17.5 Dong Bao Recent Development
12.18 Ganlee
12.18.1 Ganlee Corporation Information
12.18.2 Ganlee Description and Business Overview
12.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Ganlee Products Offered
12.18.5 Ganlee Recent Development
12.19 United Laboratories
12.19.1 United Laboratories Corporation Information
12.19.2 United Laboratories Description and Business Overview
12.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.19.4 United Laboratories Products Offered
12.19.5 United Laboratories Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Biologics and Biosimilars Industry Trends
13.2 Biologics and Biosimilars Market Drivers
13.3 Biologics and Biosimilars Market Challenges
13.4 Biologics and Biosimilars Market Restraints

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biologics and Biosimilars Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Monoclonal Antibodies
Table 3. Major Manufacturers of Interferon
Table 4. Major Manufacturers of Erythropoietin
Table 5. Major Manufacturers of Insulin
Table 6. Major Manufacturers of Vaccines
Table 7. Major Manufacturers of Others
Table 8. Global Biologics and Biosimilars Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 9. Global Biologics and Biosimilars Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 10. Global Biologics and Biosimilars Sales by Regions (2016-2021) & (K Units)
Table 11. Global Biologics and Biosimilars Sales Market Share by Regions (2016-2021)
Table 12. Global Biologics and Biosimilars Revenue by Regions (2016-2021) & (US$ Million)
Table 13. Global Biologics and Biosimilars Sales Forecast by Region (2022-2027) & (K Units)
Table 14. Global Biologics and Biosimilars Sales Market Share Forecast by Region (2022-2027)
Table 15. Global Biologics and Biosimilars Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 16. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2022-2027)
Table 17. Global Biologics and Biosimilars Sales by Manufacturers (2016-2021) (K Units)
Table 18. Global Biologics and Biosimilars Sales Share by Manufacturers (2016-2021)
Table 19. Ranking of Global Top Biologics and Biosimilars Manufacturers by Revenue (US$ Million) in 2020
Table 20. Biologics and Biosimilars Revenue by Manufacturers (2016-2021) (US$ Million)
Table 21. Biologics and Biosimilars Revenue Share by Manufacturers (2016-2021)
Table 22. Global Biologics and Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 23. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2020)
Table 24. Key Manufacturers Biologics and Biosimilars Price (2016-2021) (USD/Unit)
Table 25. Biologics and Biosimilars Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Biologics and Biosimilars Product Type
Table 27. Date of International Manufacturers Enter into Biologics and Biosimilars Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Biologics and Biosimilars Sales by Type (2016-2021) (K Units)
Table 30. Global Biologics and Biosimilars Sales Share by Type (2016-2021)
Table 31. Global Biologics and Biosimilars Revenue by Type (2016-2021) (US$ Million)
Table 32. Global Biologics and Biosimilars Revenue Share by Type (2016-2021)
Table 33. Biologics and Biosimilars Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 34. Global Biologics and Biosimilars Sales Forecast by Type (2022-2027) & (K Units)
Table 35. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2022-2027)
Table 36. Global Biologics and Biosimilars Revenue Forecast V (2022-2027) & (US$ Million)
Table 37. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2022-2027)
Table 38. Global Biologics and Biosimilars Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 39. Global Biologics and Biosimilars Sales by Application (2016-2021) (K Units)
Table 40. Global Biologics and Biosimilars Sales Share by Application (2016-2021)
Table 41. Global Biologics and Biosimilars Revenue by Application (2016-2021) (US$ Million)
Table 42. Global Biologics and Biosimilars Revenue Share by Application (2016-2021)
Table 43. Biologics and Biosimilars Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 44. Global Biologics and Biosimilars Sales Forecast by Application (2022-2027) & (K Units)
Table 45. Global Biologics and Biosimilars Sales Market Share Forecast by Application (2022-2027)
Table 46. Global Biologics and Biosimilars Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 47. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2022-2027)
Table 48. Global Biologics and Biosimilars Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 49. China Biologics and Biosimilars Sales (K Units) of Key Companies (2016-2021)
Table 50. China Biologics and Biosimilars Sales Share by Company (2016-2021)
Table 51. China Biologics and Biosimilars Revenue (US$ Million) by Company (2016-2021)
Table 52. China Biologics and Biosimilars Revenue Share by Company (2016-2021)
Table 53. China Biologics and Biosimilars Sales (K Units) by Type (2016-2021)
Table 54. China Biologics and Biosimilars Sales Share by Type (2016-2021)
Table 55. China Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2016-2021)
Table 56. China Biologics and Biosimilars Price (USD/Unit) by Type (2016-2021)
Table 57. China Biologics and Biosimilars Sales (K Units) by Type (2022-2027)
Table 58. China Biologics and Biosimilars Sales Share by Type (2022-2027)
Table 59. China Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2022-2027)
Table 60. China Biologics and Biosimilars Revenue Share by Type (2022-2027)
Table 61. China Biologics and Biosimilars Price (USD/Unit) by Type (2022-2027)
Table 62. China Biologics and Biosimilars Sales (K Units) by Application (2016-2021)
Table 63. China Biologics and Biosimilars Sales Share by Application (2016-2021)
Table 64. China Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2016-2021)
Table 65. China Biologics and Biosimilars Price (USD/Unit) by Application (2016-2021)
Table 66. China Biologics and Biosimilars Sales (K Units) by Application (2022-2027)
Table 67. China Biologics and Biosimilars Sales Share by Application (2022-2027)
Table 68. China Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2022-2027)
Table 69. China Biologics and Biosimilars Revenue Share by Application (2022-2027)
Table 70. China Biologics and Biosimilars Price (USD/Unit) by Application (2022-2027)
Table 71. North America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 72. North America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 73. North America Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 74. North America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 75. Asia Pacific Biologics and Biosimilars Sales by Region (2016-2021) & (K Units)
Table 76. Asia Pacific Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 77. Asia Pacific Biologics and Biosimilars Revenue by Region (2016-2021) & (US$ Million)
Table 78. Asia Pacific Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Table 79. Europe Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 80. Europe Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 81. Europe Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 82. Europe Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 83. Latin America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 84. Latin America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 85. Latin Americaa Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 86. Latin America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 87. Middle East and Africa Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 88. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 89. Middle East and Africa Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 90. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 91. Roche Corporation Information
Table 92. Roche Description and Business Overview
Table 93. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 94. Roche Biologics and Biosimilars Product
Table 95. Roche Recent Development
Table 96. Amgen Corporation Information
Table 97. Amgen Description and Business Overview
Table 98. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 99. Amgen Product
Table 100. Amgen Recent Development
Table 101. AbbVie Corporation Information
Table 102. AbbVie Description and Business Overview
Table 103. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 104. AbbVie Product
Table 105. AbbVie Recent Development
Table 106. Sanofi-Aventis Corporation Information
Table 107. Sanofi-Aventis Description and Business Overview
Table 108. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 109. Sanofi-Aventis Product
Table 110. Sanofi-Aventis Recent Development
Table 111. Johnson & Johnson Corporation Information
Table 112. Johnson & Johnson Description and Business Overview
Table 113. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 114. Johnson & Johnson Product
Table 115. Johnson & Johnson Recent Development
Table 116. Pfizer Corporation Information
Table 117. Pfizer Description and Business Overview
Table 118. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 119. Pfizer Product
Table 120. Pfizer Recent Development
Table 121. Novo Nordisk Corporation Information
Table 122. Novo Nordisk Description and Business Overview
Table 123. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 124. Novo Nordisk Product
Table 125. Novo Nordisk Recent Development
Table 126. Eli Lilly Corporation Information
Table 127. Eli Lilly Description and Business Overview
Table 128. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 129. Eli Lilly Product
Table 130. Eli Lilly Recent Development
Table 131. Novartis Corporation Information
Table 132. Novartis Description and Business Overview
Table 133. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 134. Novartis Product
Table 135. Novartis Recent Development
Table 136. Merck Corporation Information
Table 137. Merck Description and Business Overview
Table 138. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 139. Merck Product
Table 140. Merck Recent Development
Table 141. 3sbio Corporation Information
Table 142. 3sbio Description and Business Overview
Table 143. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 144. 3sbio Product
Table 145. 3sbio Recent Development
Table 146. Changchun High Tech Corporation Information
Table 147. Changchun High Tech Description and Business Overview
Table 148. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 149. Changchun High Tech Product
Table 150. Changchun High Tech Recent Development
Table 151. CP Guojian Corporation Information
Table 152. CP Guojian Description and Business Overview
Table 153. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 154. CP Guojian Product
Table 155. CP Guojian Recent Development
Table 156. Biotech Corporation Information
Table 157. Biotech Description and Business Overview
Table 158. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 159. Biotech Product
Table 160. Biotech Recent Development
Table 161. Gelgen Corporation Information
Table 162. Gelgen Description and Business Overview
Table 163. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 164. Gelgen Product
Table 165. Gelgen Recent Development
Table 166. Innovent Corporation Information
Table 167. Innovent Description and Business Overview
Table 168. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 169. Innovent Product
Table 170. Innovent Recent Development
Table 171. Dong Bao Corporation Information
Table 172. Dong Bao Description and Business Overview
Table 173. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 174. Dong Bao Product
Table 175. Dong Bao Recent Development
Table 176. Ganlee Corporation Information
Table 177. Ganlee Description and Business Overview
Table 178. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 179. Ganlee Product
Table 180. Ganlee Recent Development
Table 181. United Laboratories Corporation Information
Table 182. United Laboratories Description and Business Overview
Table 183. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 184. United Laboratories Product
Table 185. United Laboratories Recent Development
Table 186. Biologics and Biosimilars Market Trends
Table 187. Biologics and Biosimilars Market Drivers
Table 188. Biologics and Biosimilars Market Challenges
Table 189. Biologics and Biosimilars Market Restraints
Table 190. Biologics and Biosimilars Customers List
Table 191. Biologics and Biosimilars Distributors List
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Sales Market Share by Type in 2020 & 2027
Figure 3. Monoclonal Antibodies Product Picture
Figure 4. Interferon Product Picture
Figure 5. Erythropoietin Product Picture
Figure 6. Insulin Product Picture
Figure 7. Vaccines Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics and Biosimilars Sales Market Share by Application in 2020 & 2027
Figure 10. Tumor
Figure 11. Diabetes
Figure 12. Cardiovascular
Figure 13. Hemophilia
Figure 14. Others
Figure 15. Biologics and Biosimilars Report Years Considered
Figure 16. Global Biologics and Biosimilars Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Biologics and Biosimilars Market Size 2016-2027 (US$ Million)
Figure 18. Global Biologics and Biosimilars Sales 2016-2027 (K Units)
Figure 19. Global Biologics and Biosimilars Market Size Market Share by Region: 2021 Versus 2027
Figure 20. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Figure 21. Global Biologics and Biosimilars Sales Market Share by Region in 2020
Figure 22. Global Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Figure 23. Global Biologics and Biosimilars Revenue Market Share by Region in 2020
Figure 24. Global Biologics and Biosimilars Sales Share by Manufacturer in 2020
Figure 25. The Top 10 and 5 Players Market Share by Biologics and Biosimilars Revenue in 2020
Figure 26. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 27. Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Figure 28. Global Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 29. Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
Figure 30. Global Biologics and Biosimilars Revenue Market Share by Type in 2020
Figure 31. Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Figure 32. Global Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 33. Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
Figure 34. Global Biologics and Biosimilars Revenue Market Share by Application in 2020
Figure 35. China Biologics and Biosimilars Sales Growth Rate 2016-2027 (K Units)
Figure 36. China Biologics and Biosimilars Revenue Growth Rate 2016-2027 (US$ Million)
Figure 37. China Biologics and Biosimilars Market Share in Global Market 2016-2027
Figure 38. China 5 and 10 Largest Biologics and Biosimilars Players Market Share by Revenue in Biologics and Biosimilars in 2020
Figure 39. China Biologics and Biosimilars Revenue Share by Type (2016-2021)
Figure 40. China Biologics and Biosimilars Revenue Growth Rate by Type in 2016 & 2020
Figure 41. China Biologics and Biosimilars Revenue Share by Application (2016-2021)
Figure 42. China Biologics and Biosimilars Revenue Growth Rate by Application in 2016 & 2020
Figure 43. North America Biologics and Biosimilars Sales Growth Rate 2016-2021 (K Units)
Figure 44. North America Biologics and Biosimilars Revenue Growth Rate 2016-2021 (US$ Million)
Figure 45. North America Biologics and Biosimilars Sales Market Share by Country in 2020
Figure 46. North America Biologics and Biosimilars Revenue Market Share by Country in 2020
Figure 47. U.S. Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 48. U.S. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Canada Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 50. Canada Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. Europe Biologics and Biosimilars Sales Growth Rate 2016-2021 (K Units)
Figure 52. Europe Biologics and Biosimilars Revenue Growth Rate 2016-2021 (US$ Million)
Figure 53. Europe Biologics and Biosimilars Sales Market Share by Country in 2020
Figure 54. Europe Biologics and Biosimilars Revenue Market Share by Country in 2020
Figure 55. Germany Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 56. Germany Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 57. France Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 58. France Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 59. U.K. Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 60. U.K. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 61. Italy Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 62. Italy Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 63. Russia Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 64. Russia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 65. Asia Pacific Biologics and Biosimilars Sales Growth Rate 2016-2021 (K Units)
Figure 66. Asia Pacific Biologics and Biosimilars Revenue Growth Rate 2016-2021 (US$ Million)
Figure 67. Asia Pacific Biologics and Biosimilars Sales Market Share by Region in 2020
Figure 68. Asia Pacific Biologics and Biosimilars Revenue Market Share by Region in 2020
Figure 69. China Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 70. China Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 71. Japan Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 72. Japan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 73. South Korea Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 74. South Korea Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 75. India Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 76. India Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 77. Australia Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 78. Australia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 79. Taiwan Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 80. Taiwan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 81. Indonesia Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 82. Indonesia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 83. Thailand Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 84. Thailand Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 85. Malaysia Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 86. Malaysia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 87. Philippines Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 88. Philippines Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 89. Vietnam Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 90. Vietnam Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 91. Latin America Biologics and Biosimilars Sales Growth Rate 2016-2021 (K Units)
Figure 92. Latin America Biologics and Biosimilars Revenue Growth Rate 2016-2021 (US$ Million)
Figure 93. Latin America Biologics and Biosimilars Sales Market Share by Country in 2020
Figure 94. Latin America Biologics and Biosimilars Revenue Market Share by Country in 2020
Figure 95. Mexico Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 96. Mexico Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 97. Brazil Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 98. Brazil Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 99. Argentina Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 100. Argentina Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 101. Middle East and Africa Biologics and Biosimilars Sales Growth Rate 2016-2021 (K Units)
Figure 102. Middle East and Africa Biologics and Biosimilars Revenue Growth Rate 2016-2021 (US$ Million)
Figure 103. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country in 2020
Figure 104. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country in 2020
Figure 105. Turkey Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 106. Turkey Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 107. Saudi Arabia Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 108. Saudi Arabia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 109. U.A.E Biologics and Biosimilars Sales Growth Rate (2016-2021) (K Units)
Figure 110. U.A.E Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 111. Biologics and Biosimilars Value Chain
Figure 112. Channels of Distribution
Figure 113. Distributors Profiles
Figure 114. Bottom-up and Top-down Approaches for This Report
Figure 115. Data Triangulation
Figure 116. Key Executives Interviewed

---